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Abstract The mammary gland is a unique organ in that it
undergoes most of its development after birth under the
control of systemic hormones. Whereas in most other
organs stem cells divide in response to local stimuli, to
replace lost cells, in the mammary gland large numbers of
cells need to be generated at specific times during puberty,
estrous cycles and pregnancy to generate new tissue
structures. This puts special demands on the mammary
stem cells and requires coordination of local events with
systemic needs. Our aim is to understand how the female
reproductive hormones control mammary gland develop-
ment and influence tumorigenesis. We have shown that
steroid hormones act in a paracrine fashion in the mammary
gland delegating different functions to locally produced
factors. These in turn, affect cell–cell interactions that result
in changes of cell behavior required for morphogenesis and
differentiation. Here, we discuss how these hormonally
regulated paracrine interactions may impinge on stem cells
and the stem cell niche and how this integration of signals
adds extra levels of complexity to current mammary stem
cell models. We propose a model whereby the stem cell
niches change depending on the developmental stages and
the hormonal milieu. According to this model, repeated
hormone stimulation of stem cells and their niches in the
course of menstrual cycles may be an important early event
in breast carcinogenesis and may explain the conundrum
why breast cancer risk increases with the number of
menstrual cycles experienced prior to a first pregnancy.
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Mammary Gland Development
The mammary gland is a unique organ in that it undergoes
most of its development after birth. In utero, mammary
placodes form in the ventral skin of the embryo through
epithelial–mesenchymal interactions. The placodes give rise
to buds that grow into the underlying stroma and
subsequently sprout to form rudimentary ductal systems,
which are embedded in specialized stroma, the mammary
fat pads. Until puberty, the mammary glands grow
isometrically with the rest of the body [1, 2].
With the onset of puberty and ovarian function,
development of the ductal system accelerates dramatically.
The tips of the ducts enlarge to form club-shaped structures,
called terminal end buds (TEBs), which contain highly
proliferative cells. The ducts penetrate the fat pad by
branching dichotomously until they reach the edge of the
fat pad [1]. With sexual maturity and the establishment of
regular estrous cycles, the ductal system gains further
complexity through the addition of side branches. Lateral
branching is further enhanced during pregnancy. Later
during pregnancy, little saccular outpouchings called alveoli
bud all over the ductal system. This leads to a substantial
increase in functional surface and enables the mammary
gland to produce copious amounts of milk when the pups
are born and begin to suckle. Once the pups are weaned,
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involution begins involving massive apoptosis and loss of
alveolar structures [1].
Hormonal Control
Ovarian estrogens and progestins are pivotal regulators of
female reproductive function including breast development.
Upon maturation of the hypothalamic-anterior pituitary–
ovarian axis, in response to episodic release of gonadotro-
pin-releasing hormone, surges in secretion of pituitary
follicle stimulating hormone (FSH) and luteinizing hor-
mone (LH) trigger cyclic maturation ovarian follicles and of
ovarian steroid production. The menstrual cycle in humans
begins with the follicular phase characterized by FSH
induced maturation of ovarian follicles that is accompanied
by high estrogen secretion. The LH surge at mid cycle
triggers the release of the egg whereas the remnant follicle
will become the corpus luteum and secrete increasing
amounts of progesterone characteristic of the post ovulato-
ry, luteal phase of the cycle. During the first year and a half,
cycles are irregular, anovulatory and have no luteal phase.
In mice, the situation is similar. Puberty begins at 3 weeks
of age, with the ovaries secreting increasing amounts of
estrogens. Usually around 8 weeks of age, regular estrous
cycles are established with cyclic peaks in serum progester-
one levels, sexual maturity is reached. In the mammary
gland, at this stage, the ducts have reached the edge of the fat
pad, subsequent proliferation results in the formation of side
branches.
When a pregnancy is established, the corpus luteum
increases progesterone synthesis and secretion until the
placenta takes over this steroidogenic function to ensure the
characteristically high progestin levels of pregnancy. Later
in pregnancy, pitutitary prolactin becomes important for the
formation of the secretory alveoli and differentiation of the
mammary epithelial cells into milk secreting cells [3].
Stem Cells and the Stem Cell Niche: Concepts
and Assays
Mouse mammary stem cells have been functionally defined
as cells that are able to reconstitute an epithelium-divested
mammary fat pad. For this assay, the nipple-near half of the
inguinal mammary gland of 3-week-old, prepubertal,
female mice that contains the rudimentary ductal tree is
surgically removed leaving behind stroma devoid of
epithelium [4]. Primary mammary epithelial cells injected
into this “cleared fat pad” will reassemble and grow out
behaving like the endogenous epithelium with the only
difference being that the newly formed ductal system does
not connect to the nipple and hence secretions cannot be
released. Combining this assay with the power of fluores-
cence activated cell sorting (FACS), a series of elegant
studies have recently characterized cell populations in the
mammary gland that are enriched for stem cells [5–8], as
reviewed elsewhere in this issue.
A description of stem cells based on morphological
hallmarks has been elaborated by G. Smith and various
collaborators. Their studies have shown that small light
cells (SLC) bearing morphological characteristics of undif-
ferentiated cells exist in both mice and rats [9–11]. The
percentage of SLCs in the cell population does not change
even during pregnancy as cell number increases manifold
[12]. The number of SLCs decreases as epithelium is
transplanted serially and looses reconstitution potential.
Moreover, SLCs are located basally and never touch the
lumen; hence, they are likely to be comprised in the stem
cell enriched populations identified by immunotyping and
FACS as the Lin− SCA-1low CD24med, CD49f high com-
partment that shows characteristics of basally located cells
[6, 10]. All these findings make the SLCs attractive
candidates, but the formal proof that they are indeed the
reconstituting cells remains to be provided.
The stem cell niche is the microenvironment surrounding
stem cells that maintains their stemness and prevents them
from differentiating [13–15]. It comprises signaling cells,
characteristic extracellular matrix (ECM) and the stem cell
[9, 16]. The most impressive evidence of the power of the
mammary gland stem cell niche was provided by the recent
demonstration that it is able to redirect spermatogenic fate
[17]. When genetically marked cells from adult seminifer-
ous tubules were mixed with single cell suspensions of
mammary epithelial cells and injected into cleared fat pads,
they contributed to all aspects of the reconstitution.
Moreover, the reprogrammed testicular cells were able to
reconstitute upon serial transplantation [17].
The identity of stem cell niches within the mouse
mammary gland has not been defined for lack of molecular
markers; in the human breast, however, several markers
have recently be ascertained [18].
Similarly, the frequency at which stem cells and/or stem
cell niches occur in the mammary gland is still a matter of
contention. Independent of the developmental stage, mam-
mary epithelium taken from any area of the mammary
gland is able to fully reconstitute a ductal tree when grafted
to cleared fat pads indicating that stem cells and their niches
are distributed at regular intervals throughout the ductal
system throughout development (Fig. 1). Estimates of how
frequent stem cells are in the mouse mammary epithelium,
based on serial dilution experiments in the fat pad
reconstitution assay, vary between 1 mammary repopulating
unit (MRU) in 200 dissociated cells [19] to 1 in 5,000
dissociated cells [5].
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Control of Stem Cells and the Stem Cell Niche
by Hormones and Cell–Cell Interactions
Our laboratory is interested in understanding how the
female reproductive hormones control mammary gland
development and influence breast tumorigenesis. Combin-
ing the use of hormone receptor deficient mice with tissue
recombination techniques, we and others have revealed that
the hormones act sequentially on the mammary gland
through their respective receptors in the epithelium (Fig. 2).
Estrogens and progestins, drive ductal elongation and
side branching respectively; both processes involve exten-
sive cell proliferation. We propose that the two hormones
signaling through their respective receptors expressed on a
subset of luminal epithelial cells induce the expression of
local factors that trigger the assembly and the activation of
the stem cell niche. In this way the activity of stem cells
and their niches respond to a systemic stimulus, which in
turn reflects systemic requirements.
During estrogen-driven ductal outgrowth, stem cells at
the tip of the growing ducts, called cap cells, are in direct
contact with the stroma because the basal lamina is
disrupted in this zone. Thus, stromal cells can be recruited
to fulfill the niche cell function (Fig. 3). During progester-
one-induced lateral branching, the basal lamina may
become thinner but remains intact, and myoepithelial cells
are recruited to form the niche (Fig. 4). Thus the
composition of the niche varies related to the requirements
of the specific developmental stage. Both models will be
discussed below in the context of recent work from our lab.
Estrogen and the Stem Cell Niche
Role of Estrogen Signaling in the Mammary Gland
The role of estrogens in mammary gland development is
illustrated by the finding that pubertal ductal outgrowth
comes to a halt when the ovaries are removed. Outgrowth is
restored when 17-β-estradiol is administered locally by
means of slow release pellets grafted to the mammary gland
[20]. Consistent with estrogens driving ductal outgrowth, in
mammary glands of mice deficient for the estrogen receptor
α (ERα), the prime mediator of estrogen function, a normal
rudimentary ductal system is formed but subsequent
development is blocked. When ERα deficient epithelium
is grafted to cleared fat pads of wild type (wt) mice it does
not develop indicating that ERα signaling in the mammary
epithelium is essential for ductal outgrowth.
estrogen progesterone prolactin
rudimentary               ductal elongation/bifurcation              sidebranching alveologenesis
ductal system lactogenic differentiation
Fig. 2 Schematic representation of mammary gland development
(black) and hormonal control (red) of different morphogenetic steps.
Tissue recombination experiments with hormone receptor deficient mouse
strains revealed that the female reproductive hormones estrogens,
progesterone, and prolactin act sequentially during mammary gland
development through their respective receptors in the mammary epithelium
Placode Formation           Mammary Bud         Ductal elongation               Sidebranching
Mammary 
Stem Cell
Fig. 1 Stem cell distribution at
different stages of mammary
gland development. Schematic
representation of distinct stages
of mammary gland development
with respective distribution of
stem cells, not drawn to scale.
Mammary epithelium taken
from any area of the mammary
gland is able to fully reconstitute
a ductal tree when grafted to
cleared fat pads indicating that
stem cells and their niches are
distributed at regular intervals
throughout the mammary gland
Stem Cell Rev (2007) 3:147–156 149
When chimaeric epithelia are generated using wt and
ERα deficient mouse mammary epithelial cells to recon-
stitute cleared fat pads, ERα deficient cells, identified
based on the expression of the marker gene, contribute
extensively to the ductal outgrowth. The mutant cells are
found both in the outer cap cell layer and in the subtending
body cell compartment of the TEBs of the growing ducts
as well as in the luminal and the myoepithelial cell layer of
mature ducts [21].
Two conclusions can be drawn. First, ERα deficient
mammary epithelia contain stem cells. Second, the ERα
deficient stem cells can only unfold their potential when
assisted by ERα positive cells.
The first conclusion is in line with various findings
indicating that mammary stem cells are ERα negative. The
observation that transplantation of the mammary anlage
(see, Fig. 1), which only contains ERα negative cells [22],
results in full reconstitution of the mammary gland [23],
implicates that mouse mammary stem cells are steroid
receptor negative. Recent characterization of stem cell
enriched populations by FACS, established that stem cells in
the adult mammary gland are enrichedwithin a cell population
that does not express ERα [8]. Sleeman et al. demonstrated
that even large numbers of steroid receptor positive cells
identified as CD24high and CD133high (prominin) population
by FACS sorting, fail to reconstitute a mammary gland when
transplanted into a cleared fat pad whereas prominin negative
cells give rise to ductal outgrowth [7].
Thus, mammary stem cells appear to be ERα negative
throughout development, yet, they require the presence of
ERα positive cells, that we will name the “sensor cells”.
The “sensor cells” detect the systemic estrogen stimulus
and translate it to subsequent local events that result in the
stem cells dividing and unfolding their potential.
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Fig. 3 Model of the pubertal stem cell niche. Shown is a schematic
representation of a terminal end bud (TEB) during estrogen-driven
ductal outgrowth. Estrogens acting on the luminal sensor cell induce the
secretion of amphiregulin. The growth factor is released by epithelial
ADAM17 and acts on EGFR on stromal cells. The stromal cells in turn
release FGFs and the TGF-β inhibitor, decorin. Activation of FGF
signaling in the stem cells and downmodulation of TGF- β signaling
allow for stem cell proliferation a prerequisite for ductal elongation. Note,
that the basal lamina is disrupted and the stem cells are in direct contact
with stromal cells that act as niche cells at this stage
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Amphiregulin as Downstream Mediator of Estrogen
Signaling
How does estrogen elicit its paracrine effects? How can
estrogen stimulate the ERα negative stem cells and their
daughter cells? Epidermal growth factor (EGF), like 17-β-
estradiol, restores ductal outgrowth when administered
locally in the mammary glands of ovariectomized pubertal
mice [24] implicating that EGF receptor (EGFR) signaling is
important downstream of ERα signaling. Amphiregulin is the
only EGF family member the transcription of which is
induced by estrogen at a time of exponential expansion of
the ductal system in the mammary glands of pubertal mice
[25]. Infact, estrogens induce amphiregulin through the ERα
and require amphiregulin to induce proliferation of the
mammary epithelium. Consequently, amphiregulin deficient
mammary epithelia do not form TEBs and do not invade the
fat pad in virgin mice. Like ERα deficient cells, amphir-
egulin−/− mammary epithelial cells are rescued by neighbour-
ing wt cells. In chimeric epithelia, mutant cells proliferate
and contribute to all epithelial cell compartments of the
ductal outgrowth [25]. These observations indicate that
amphiregulin, like estrogens signals in a paracrine fashion
and are consistent with amphiregulin being the important
clue provided to the stem cells and their progeny by an ERα
positive neighbouring cell.
When two differentially marked wt cell populations are
used to reconstitute cleared fat pads, distinct patterns of
chimerism are found. In one type, entire ductal segments are
made of cells expressing one single marker, in the other type,
ducts displayed a patchwork of the twomarkers (L. Ciarloni et
al., unpublished observations). On the other hand, when either
ERα or amphiregulin deficient cells are mixed with wt cells,
the mutant cells never give rise to an entire ductal segment but
are only observed in the patchy type of chimerism, never more
than 3–4 cell diameters away from wt cells. This strongly
suggests that close interactions are required during ductal
outgrowth to relegate the estrogen-induced signals to
ERα negative stem and/or progenitor cells. Whether direct
cell–cell contact is required or signals can travel over several
cell diameters remains to be addressed.
It is tempting to speculate that the high number of stem
cells necessitated by the large cell number expansion that
the mammary gland undergoes during development, ren-
ders this organ particularly prone to carcinogenesis.
Model of the Estrogen-Driven Stem Cell Niche
Is amphiregulin the stimulus that makes ERα negative stem
cells divide? Intriguingly, EGFR mRNA is enriched in the
stem cell containing compartment [8]. Yet, genetic evidence
indicates that the EGFR is required in the mammary
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Fig. 4 Model of the adult stem cell niche that is activated in response
to progesterone released by the ovaries during estrous cycles and
pregnancy. The basal lamina remains intact and myoepithelial cells are
recruited to fulfill niche cell function. Progesterone acting on the
luminal sensor cell induces wnt-4 and RANKL. The secreted wnt-4
activates the stem cell compartment acting either directly on the stem
cells and/or indirectly via the niche cells. RANKL, on the other hand
induces proliferation of neighboring luminal cells through induction of
cyclin D1
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stroma; wt epithelium does not grow out in EGFR deficient
stroma whereas EGFR deficient epithelium does reconsti-
tute when placed into a wt fat pad [26]. Although these data
do not preclude additional, direct effects on the epithelial
cells, they strongly argue that the prime target for
amphiregulin is the stroma. Infact, during ductal outgrowth
a unique situation arises during mammary gland develop-
ment; at the TEBs, the outer epithelial cells, the cap cells,
which are considered to be stem cells, directly interact with
stromal cells because the basal lamina that usually separates
epithelial and stromal compartments, is degraded.
Thus, a picture emerges of a stem cell niche consisting of
three different cells; the ERα positive sensor cell, the EGFR
positive stromal cell and the ERα negative stem cell (Fig. 3).
All of them remain quiescent until they are “switched on” by
estrogens. In response to estrogens, the “sensors” synthesize
and secrete amphiregulin. Membrane-bound amphiregulin is
subsequently activated by ADAM17, which is also of epithelial
origin but not necessarily produced by the sensor cells [27]. The
activated amphiregulin in turn acts on stromal cells.
The identity of the stromal factors that talk back to the
epithelial components of the stem cell niche remains to be
revealed. Work of Z. Werb and colleagues has unraveled
several attractive candidates, partly through expression
microarrays, partly by inference from in vitro culture models
[28–30]. Thus, the stroma might respond by releasing and
activating metalloproteinases such as MMP14 or MMP2,
reported EGFR targets that are required to restructure of the
ECM by degrading collagen type I and to release of other
growth factors and [31]. FGF 7 and FGF 2 are particularly
attractive candidates to mediate a proliferative signal from
the stroma, both have been shown to induce ductal
morphogenesis in a 3D matrigel assay. Interestingly, bFGF
is a critical component in mammosphere medium suggest-
ing that activation of FGF signaling is important to stem
cells [32]. Whether FGF acts directly on the stem cell or
indirectly via other niche cells remains to be determined.
It is also conceivable that growth inhibitory influences
exerted by TGF-β signaling are relieved by a stromal
derived factor. This could happen extracellularly through
the secretion of the TGF-β inhibitor decorin [33] or
intracellularly through induction of expression of inhibitory
SMADs. Intriguingly, decorin was among the genes highly
expressed in mammospheres [32]. Activation of EGFR and
possibly other receptor tyrosine kinases, as well as of NF-
κB or signal transducer and activator of transcription
(STAT) induced by cytokine receptor signaling can result
in the transcription of SMAD-6 and-7 [34].
Besides the fibroblasts, the stroma also includes adipo-
cytes and endothelial cells which are not featured in our
model (Fig. 3). Furthermore, communication with infiltrat-
ing immune cells may comprise another very important
level of regulation [35].
Progesterone and the Stem Cell Niche
At the end of puberty, when the ductal system reaches the
edges of the mammary fat pad and the mouse is sexually
mature, 17-β-estradiol almost completely looses its mito-
genic effects. Proliferation and morphogenesis are now
driven by progesterone, serum levels of which rise with
each estrous cycle and during pregnancy (R. Rajaram,
Brisken unpublished observations).
Progesterone can elicit proliferation of both receptor
positive and receptor negative luminal epithelial cells and
acts, like estrogens, in a paracrine fashion [36]. At least two
players are induced and have been implicated in mediating
the hormone’s paracrine effects, the Receptor Activator for
Nuclear Factor κB Ligand (RANKL) [37, 38] and wnt-4
[23] (Fig. 4). It has been suggested that RANKL is
important in eliciting proliferation through induction of
cyclin D1 in neighboring cells [37–39]. Wnt signaling, on
the other hand, has been implicated in the control of stem
cells [40–43] and this may account for its strong oncogenic
effects.
We envision a scenario in which the sensor cell responds
to progesterone stimulation by synthesizing and secreting
wnt-4. Wnt-4 mobilizes stem cells either acting on them
directly or indirectly through activation of niche cells. This
activation results in an asymmetric cell division yielding a
new stem cell and a daughter cell that give rise, possibly
through further asymmetric cell divisions to transient
amplifying cells. These cells in turn are induced to
proliferate by RANKL.
The Ever-Changing Stem Cell Niche
The mammary stem cells need to respond to distinct factors
at distinct developmental stages. The initial stages of
mammary gland development, we did not discuss here, are
thought to be controlled by epithelial–mesenchymal cross
talk involving PTHrP [44–46], BMP [47], FGF 10 [48, 49],
and Wnt signaling [50, 51]. During puberty, estrogen
controls the stem cell niche with amphiregulin and EGFR
signaling being of central importance. In the adult mam-
mary gland, progesterone is the major stimulant of stem/
progenitor cell stimulation and a prime mediator is wnt-4.
The highly specific requirement of EGFR versus wnt
signaling in response to either estrogens or progestins,
respectively, is underlined by the following observations:
In contrast to ERα deficient epithelia that do not
proliferate throughout all developmental stages, amphire-
gulin−/− mammary epithelia undergo subsequent develop-
mental steps i.e. side branching and alveologenesis. This
argues that estrogens specifically require amphiregulin to
exert their effects whereas progesterone, which also induces
amphiregulin expression [52], does not require its presence.
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Different wnts, such as wnt-2 and wnt-5a [28], are
expressed in the TEBs, yet, wnt signaling is specifically
required to mediate progesterone function. Ectopic expres-
sion of wnt-1 in the ERα deficient background by means of
the MMTV-wnt-1 transgene did not lead to a rescue of the
ductal elongation phenotype [53]. Ectopic wnt activation
did, however, overcome the side branching defect in this
mutant, furthermore it rescued the phenotype of PR deficient
mammary epithelium [23]. These findings suggest that the
stem cell promoting effects of wnt signaling are specific to
progesterone-induced events and are not involved in the
estrogen-induced activation of the stem cell niche.
We propose that the niches that promote estrogen- and
progesterone-induced stem cell expansion are overlapping
entities. Thus, the hormone receptor positive sensor cell and
the stem cell are identical but the niche cell that is recruited
in response to estrogens versus progesterone is different.
What about the sensor cells, how special are they? After
all, in the adult virgin more than 30% of the luminal cells
may be expressing steroid receptors; do they all induce
stem cell niches or are there different subpopulations of
ERα/PR positive cells, those that control stem cells and
those that stimulate proliferation of transient amplifying
cells? Maybe all the ERα/PR positive cells do the same job
and release the same factors, but the biological outcome on
the part of the responding cell is determined by the
differentiation state of the responding cell. Alternatively,
the impact of the steroid receptor positive cells is an
indirect one only. They induce proliferation of luminal
epithelial cells, which leads to depletion of progenitor cells;
this depletion is sensed by the stem cell niche, which reacts
by stimulating asymmetric divisions of the stem cell.
Breast Cancer: Messing Around with the Stem
Cell Niche
The stem cell theory provides an attractive model that
accounts for chemo resistance and tumor heterogeneity
[54–57]. What is the relevance of our models to human
breast cancer? Is breast cancer a disease of stem cells and
their niches?
The Progesterone-Wnt Connection
Progesterone exposure, as experienced by premenopausal
women during menstrual cycles and by postmenopausal
women under hormone replacement therapy, increases
breast cancer risk [58]. We speculate that this may be due
to stimulation of stem cells.
As discussed, wnt signaling is important in mediating
progesterone action [23] and evidence has accumulated that it
is involved in stem cells self-renewal in different organs [41]
including the mammary gland [42, 43]. Intriguingly, the wnt
pathway has long been established as strongly oncogenic in
the mouse mammary gland, yet, a role of wnt signaling in
human breast cancer has not been forthcoming because
mutations in intracellular signaling components such as β-
catenin and APC were not identified [59]. More recently,
however, evidence has accumulated that the secreted
inhibitor of wnt signaling, secreted frizzled related protein-1
(SFRP-1), is down modulated during breast carcinogenesis
suggesting that activation of the pathway may occur [60]. To
assess whether deregulation of wnt signaling in human breast
epithelial cells may perturb their homeostasis, we ectopically
expressed Wnt-1 in them using a retroviral vector. The
increased wnt signaling activity triggered a cascade of events
resulting in oncogenic conversion of these cells. The breast
epithelial cells ectopically expressing Wnt-1 proliferated
more than the controls. However, at passage 6 to 7, the
majority of the infected cells senesced like the control
cultures. At the same time, a more dynamic subpopulation
began to appear, which continued to proliferate and began to
detach from the dish and to grow as multi cellular aggregates.
The Wnt-1-HMECs could be dissociated, would briefly
attach and then continue to grow in suspension. Injected
into mammary glands of immuno-compromised mice, they
gave rise to tumors that showed morphological and molec-
ular hallmarks of a subtype of human breast carcinomas,
medullary carcinoma. Consistent with the wnt-1-infected cell
strains being transformed, the Rb and p53 pathways were
inactivated and the cells were triploid.
What are the mechanisms underlying this wnt-1 induced
transformation of primary human breast epithelial cells?
The first clue is, that wnt-1 expression activated a DNA
damage response. This could exert the selective pressure
necessary to inactivate checkpoints. However, other onco-
genes such as large T also induced the DNA damage
response and did so even more effectively, yet they did not
transform the infected cells. The wnt-1 transformed cells
had increased Notch signaling activity when compared to
the parental cells. Notch activation was required for both
the in vitro phenotype and in vivo tumor growth. In the
mammosphere stem cell assay Notch signaling promotes
stem cell expansion [61], reviewed in [62]. The observa-
tions that transformation is not quantitative but occurs only
in a small subset of cells and that we observe upregulation
of Notch signaling in the culture as a late event hint at the
possibility that Wnt-1 targets a particular susceptible cell
population possibly stem and/or progenitor cells that slowly
grows out. This view is further supported by our observa-
tion that the oncogenic wnt-1 cell strains express keratin 18.
Usually, expression of this marker of luminal epithelial
cells, is lost in the course of in vitro culture of primary
human breast epithelial cells; the Wnt-1-transduced cell
strains however still express keratin 18 in line with them
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being derived from a rare subset of cells with luminal
features. Thus, the strong oncogenic effects of ectopic wnt-
1 expression in both the mouse mammary gland and human
breast epithelial cells may be linked to this pathway
promoting proliferation and/or survival of a rare progeni-
tor/stem cell population.
In the mouse, wnt-4 is a progesterone target [23] that is
induced during diestrous [63]. We speculate that in the
human breast, similarly, wnt-4 or other wnts are progester-
one targets and as such are induced during the luteal phase
of the menstrual cycle in ERα/PR receptor positive luminal
cells. The wnt activates stem cells either directly or
indirectly via niche cells to generate a pool of transient
amplifying cells in anticipation of a potential pregnancy.
The repeated stimulation of progenitors, concomitant with
an activation of a DNA damage response may predispose to
malignant transformation, all the more if a given cell has
already accumulated genetic changes. This may explain
why menstrual cycles are a risk factor for breast cancer.
Perspectives
The next challenges lie in better defining stem cells and their
niches. Will we be able to identify stage-specific markers for
the niche? Are there universal niche markers; maybe the
specifics of the ECM composition do not change throughout
development?
The fat pad reconstitution assay needs to be more
standardized. Substantial variation in FACS profiles elabo-
rated in different laboratories and discrepancies in the
reconstitution potential of different cell population derive
most likely from differences in cell preparation protocols
that could readily be reduced. Eventually, the techniques
need to be applied to human breast tissue samples, although
the basic principle of hormonal control and paracrine
interactions are likely conserved among the two species
differences in the local factors that are recruited and in
surface antigens are to be expected.
The further progress is likely to have important bearings
on our understanding of the origins of breast cancer and
may open new avenues for its treatment.
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